Signup/Login
If you want to receive notifications of upcoming IPOs, you need to simply sign up or sign in with social networks.
Signup/Login
Can you determine which companies are good and which ones - the trash?
Free Pro-version
IPO Filter
Monitor
IPO today
Upcoming IPO
Priced IPO
Solaredge Technologies, Inc. (SEDG)
The Marygold Companies (MGLD)
Blue Water Vaccines (BWV)
Meihua International Medical Technologies (MHUA)
Smart for Life (SMFL)
Vivakor (VIVK)
TC BioPharm Holdings (TCBP)
Direct Digital Holdings, Llc (DRCT)
Modiv (MDV)
Sky Technologies (SKYX)
Modular Medical (MODD)
HeartCore Enterprises (HTCR)
Arcellx, Inc. (ACLX)
Silver Spike Investment Corp. (SSIC)
Maris-Tech Ltd. (MTEK)
Yoshitsu Co., Ltd. (TKLF)
Tpg Inc. (TPG)
Hillstream BioPharma (HILS)
Hour Loop (HOUR)
Vigil Neuroscience, Inc. (VIGL)
More companies

Century Therapeutics, Inc (IPSC)

Sector - Healthcare

Price chart

N/A
Return from IPO

Company News

IPO Profile

About company

Company Logo
They are an innovative biotechnology company developing transformative allogeneic cell therapies to create products for the treatment of both solid tumor and hematological malignancies with significant unmet medical need. They have created a comprehensive allogeneic cell therapy platform that includes industry-leading induced pluripotent stem cells, or iPSCs, differentiation know-how to generate immune effector cells from iPSCs, or iPSC-derived cells, clustered regularly interspaced short palindromic repeats, or CRISPR, mediated precision gene editing that allows them to incorporate multiple transgenes and remove target genes intended to optimize cell product performance, sophisticated protein engineering capabilities to develop proprietary next generation chimeric antigen receptors, or CARs, their proprietary Allo-EvasionTM technology intended to prevent rejection of their cell products by the host immune system, and cutting edge manufacturing capabilities intended to minimize product development and supply risk. They believe that these vertically integrated capabilities will allow them to further expand their existing pipeline and develop therapeutics from iPSC-derived natural killer cells, or iNK cells, or iNK, and iPSC-derived T cells, or iT cells, or iT, that may provide enhanced clinical outcomes compared to available therapeutic options.
Industry
Biological Products (no Diagnostic Substances)
CEO CFO
Osvaldo Flores -
Employees Founded
107 2018

Contacts

Address: 3675 Market Street Philadelphia, Pennsylvania 19104

Telephone: (267) 817-5790

Web page: http://www.ipsco.com

IPO information

First Trade Date 6/18/2021
Status Priced
Exchange NYSE
Lockup Period Expiration .Pro
Quiet Period Expiration .Pro
Old Price Range $20.00-$23.00
Share prices ($)

Shares & Volumes

Shares Initial (MM) 23.3
Shares Revised (MM) 10.6
Expected offer amount (MM) $199.5
Realized offer amount(MM) $212

Financial Data (last reporting year)

Market Cap (MM) $1041.58
Revenues (MM) $0
Net Income (Loss) (MM) $-53.58

Voting

What do you think will happen with the IPSC share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

Number of votes: img
The lead left underwriter: JP Morgan

IPOs led by the firm .Pro
Profitability of conducted IPOs  ?  .Pro
1st day change  ?  .Pro
Change for the first 3 months  ?  .Pro
Underwriters
JP Morgan/ BofA Securities/ SVB Leerink/ Piper Sandler
CO-Managers
-

Sector: Healthcare

Tweets about $IPSC

Tweets volume:

RT volume:

Timeframe:

Google Trends Stats